Stockholm, 2017-08-17 08:00 CEST (GLOBE NEWSWIRE) --
PledPharma announces today that Dr. Stefan Carlsson has been appointed to the newly created position as Chief Medical Officer & Vice President Clinical Development. In the role, Stefan will have the overall responsibility for the continued clinical development of the company's drug candidates PledOx® and Aladote®
Stefan Carlsson joins at a time when PledPharma is preparing for the start of the remaining clinical studies with the company's most advanced project, PledOx®, a potentially new drug for preventing nerve damage caused by chemotherapy treatment. In parallel, a proof of principle study with Aladote® to prevent the occurrence of liver damage associated with paracetamol poisoning is ongoing.
“Stefan Carlsson has a solid scientific background with over twenty years of experience from senior positions in the global pharmaceutical industry, where he has been responsible for the planning and execution of several Phase III program and contributed in bringing products to market. This has resulted in a unique ability to design and execute clinical trial programs in a way that meets global business requirements whilst maximizing the commercial value of pharmaceutical projects, both in early and late stage of development," said PledPharmas CEO Nicklas Westerholm.
Stefan Carlsson (born 1960) has a Medical Degree and a Ph.D. in physiology from Gothenburg University. He has long experience from leading positions in preclinical and clinical drug development, and has published more than thirty scientific articles, foremost in the fields of pharmacology and physiology. Stefan joins from AstraZeneca, where he held the position as Global Clinical Lead for several products on the market and products under development, including Crestor® and Epanova®. Stefan begins his employment at PledPharma on November 1, 2017.
For more information, please contact:
Nicklas Westerholm, CEO, phone: +46 73 354 20 62
Nicklas.westerholm@pledpharma.se
Michaela Gertz, CFO, phone: +46 709 26 17 75
About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
